← Back to Search

Alkylating agents

Combination Chemotherapy + Hyperthermia for Advanced Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by The University of Texas Health Science Center, Houston

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Pulmonary: FEV_1 at least 70% of predicted, Arterial PO_2 at least 60 mmHg on room air, No massive (greater than 30% involvement) lung disease, DLCO greater than 50% of predicted

Renal: Creatinine no greater than 1.8 mg/dL, Creatinine clearance at least 45 mL/min, BUN no greater than 25 mg/dL

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing the side effects of combining cisplatin, gemcitabine, interferon alfa, and whole-body hyperthermia to see if it is an effective treatment for patients with metastatic, recurrent, or refractory cancer.

Who is the study for?

Adults over 18 with advanced cancer that has spread, come back, or didn't respond to treatment can join. They need normal kidney and liver function, no severe heart or lung disease, no brain metastases or seizures, and a decent performance status. Pregnant women and those with significant emotional issues are excluded.Check my eligibility

What is being tested?

This trial tests how well the combination of chemotherapy drugs Cisplatin and Gemcitabine works with Interferon Alfa and whole-body hyperthermia (heating the body) in patients whose cancer is advanced. It's looking at safety and effectiveness.See study design

What are the potential side effects?

Possible side effects include reactions to heat like dehydration or burns; chemotherapy-related nausea, vomiting, hair loss; interferon alfa may cause flu-like symptoms; all treatments could potentially lower blood cell counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung function is mostly normal, with no severe lung disease.

Select...

My kidney function tests are within normal limits.

Select...

I am 18 years old or older.

Select...

My liver function tests are within normal limits.

Select...

My cancer has spread, come back, or is not responding to treatment.

Select...

I can care for myself but may not be able to do active work.

Select...

My blood cell counts are within a healthy range and I don't have bleeding disorders.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Duration of stable disease

Overall survival

Progression-free survival

+2 more

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor

906 Previous Clinical Trials

323,084 Total Patients Enrolled

Joan M.C. Bull, MDStudy ChairThe University of Texas Health Science Center, Houston

2 Previous Clinical Trials

82 Total Patients Enrolled

Media Library

Cisplatin (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT00004063 — Phase 1 & 2

Solid Tumors Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT00004063 — Phase 1 & 2

Cisplatin (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004063 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can people with the condition still enroll in the trial?

"This particular clinical study is not enrolling patients at the moment, as per information on clinicaltrials.gov. The trial was originally posted on 8/1/1999 and last updated on 4/29/2009; however, there are many other trials (151 to be exact) that are currently looking for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

1999. "Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00004063.

All > Mci > Texas